New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2014
04:55 EDTJNJ, JNJ, SYK, SYK, NVDQ, NVDQ, COV, COV, CNMD, CNMD, ISRG, ISRGPiper Jaffray to hold booth tours
Booth Tours at SAGES Annual Meeting will be held in Salt Lake City, Utah on April 2-3.
News For JNJ;SYK;NVDQ;COV;CNMD;ISRG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 18, 2014
07:20 EDTCOVMedtronic confirms commitment to Covidien transaction
Subscribe for More Information
November 17, 2014
07:16 EDTJNJMilken Institute--Faster Cures to hold a conference
Subscribe for More Information
November 14, 2014
17:27 EDTCOVPaulson & Co. gives quarterly update on stakes
Subscribe for More Information
16:21 EDTJNJOn The Fly: Closing Wrap
Subscribe for More Information
15:20 EDTNVDQNovadaq to host investor day
Subscribe for More Information
14:53 EDTJNJCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
12:43 EDTCOVMedtronic readying $10B bond sale for Covidien deal, WSJ reports
Subscribe for More Information
11:50 EDTCOVMedtronic readying $10B bond sale for Covidien deal, Dow reports
Subscribe for More Information
November 13, 2014
18:07 EDTCOVCovidien' VenaSeal closure system shows positive results
Covidien announced the six-month results of the VeClose pivotal study of the safety and effectiveness of the VenaSeal closure system in patients with chronic venous insufficiency having symptomatic reflux in the great saphenous vein. The VeClose randomized controlled non-inferiority study compared the safety and effectiveness of the VenaSeal system to that of the ClosureFast endovenous radiofrequency ablation catheter. Covidien's ClosureFast catheter is an endovenous radiofrequency ablation catheter designed to collapse and close enlarged leg veins. The VenaSeal system is not approved and currently limited to investigational use in the U.S. At three months, the complete closure of the great saphenous veins achieved in more than 98.9% of patients treated with the VenaSeal system compared to 95.6% of patients treated with the ClosureFast catheter. The closure rate at six months was 98.9% and 94.3%.
16:28 EDTJNJGeron announces global strategic collaboration with Janssen Biotech
Geron (GERN) announced that the company has entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, a Johnson & Johnson (JNJ) company, to develop and commercialize, imetelstat, Geron's telomerase inhibitor product candidate, for oncology, including hematologic malignancies, and other human therapeutics uses. Imetelstat is a modified oligonucleotide that is currently in early phase clinical development for myelofibrosis, or MF, and may have activity in other hematologic myeloid malignancies such as myelodysplastic syndrome, or MDS, and acute myelogenous leukemia, or AML. Under the terms of the agreement, Geron will receive an initial payment of $35M due after the applicable waiting periods under the Hart-Scott Rodino Act and is eligible to receive additional payments up to a potential total of $900M for the achievement of development, regulatory and commercial milestones, as well as royalties on worldwide net sales. Certain regulatory, development, manufacturing and promotional activities will be managed through a joint governance structure, with Janssen responsible for operational implementation of these activities. All sales will be booked by Janssen.
13:27 EDTCOVMedtronic likely to continue to make new highs, Barron's says
Subscribe for More Information
11:54 EDTJNJJanssen announces FDA approved sNDA for INVEGA SUSTENNA
Subscribe for More Information
10:44 EDTJNJMallinckrodt news on generic Concerta positive for Actavis, says BMO Capital
Subscribe for More Information
November 12, 2014
06:15 EDTNVDQJanus Capital reports 10.6% passive stake in Novadaq
Subscribe for More Information
November 11, 2014
07:24 EDTCOVMedtronic submits commitments to EU related to Covidien merger
Subscribe for More Information
November 10, 2014
15:54 EDTCOVAmerican Society of Nephrology to hold a conference
Subscribe for More Information
08:36 EDTCOVBSD Medical names Clint Carnell as president and CEO
Subscribe for More Information
07:57 EDTISRGIntuitive Surgical survey positive on hernia opportunity, says JPMorgan
JPMorgan said its survey of 25 U.S.-based general surgeons who have used da Vinci for hernia procedures yielded positive outlook on the hernia opportunity for Intuitive Surgical. The firm says the complexity of the robot does not appear to be an issue. It keeps an Overweight rating on Intuitive with a $550 price target.
07:44 EDTJNJJohnson & Johnson looks for acquisitions to help expand in China, WSJ says
Subscribe for More Information
07:28 EDTCNMDCONMED names Curt Hartman President and CEO
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use